EastGate Biotech Corp. announced its plans to take the next steps to initiate Phase III of its innovative liquid insulin mouth rinse solution, Insugin, for Type 2 diabetes patients in Pakistan. The Phase III study will be a multicenter, randomised, double-blind, placebo-controlled, parallel group study. After appropriate screening, approximately 200 male and female patients from up to 10 study centers will be treated in this study. Patients with Type 2 diabetes mellitus who are being treated by diet, exercise, untreated with antidiabetic medications or treated with and Metforrmin monotherapy or in combination with one other antidiabetic drug (excluding insulin) will be eligible for enrollment. Earlier, Insugin had met its primary endpoints in the Phase II clinical study in Pakistan demonstrating glucose management and lowering of 90-day HbA1c levels. The Phase II studies were completed in Pakistan by the company’s Joint Venture Partner, Genome Pharma/Origin Pharma. The JV partner will continue to be responsible for providing support, both in financial terms and operational activities, to conduct and carry out the Phase III studies in Pakistan.